In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

"HF algorithms are starting to recognize and include NT-proBNP in identifying stage B HF…Studies such as ours could provide insight and guidance as to when repeat measures may be useful. Future work ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...

July 16, 2009 (Uppsala, Sweden) — N-terminal pro-brain natriuretic peptide (NT-proBNP) was the only one of a panel of biomarkers that added significant prognostic information to conventional risk ...

Please provide your email address to receive an email when new articles are posted on . NT-proBNP may predict CV death, incident HF and fatal or nonfatal CV events after acute MI. The association was ...

Please provide your email address to receive an email when new articles are posted on . NT-proBNP concentration is a strong predictor of ventricular arrhythmias among people with an implantable device ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center Mortality goes up in tandem with admission natriuretic peptide levels in patients with severe ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most significant is ...

Patent ductus arteriosus (PDA) is common in preterm infants and is associated with significant morbidities. B type natriuretic peptide (BNP) is synthesized in the ventricles secondary to volume ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...